Idoven team
November 19, 2026

The ECG we already had

Manu and Chema on eight years of Idoven, and why Willem 2.0 matters to us.

I'm Manu. Before Idoven, I worked as a cardiologist, and the conversations that stayed with me were rarely about bad news. They were about late news. You meet the same patient again and again: tired for a couple of years, three different specialists, a pile of ECGs along the way, all filed as unremarkable. By the time the right answer comes, the disease has moved on.

The conversations that stayed with me were rarely about bad news. They were about late news.

I'm Chema. I'm an engineer, and I came to cardiology through data. Looking at ECGs as signals rather than pictures, what struck me was not what was missing. It was how much was there that nobody could read by eye.

We started working together in 2014. We didn't have a company yet. We had a question: how much more could a routine ECG tell us if someone could read all of it? We didn't know the answer. In many ways we're still finding out.

In 2018 we founded Idoven. The reasoning was simple, and a little stubborn. The ECG is done everywhere, every day, from primary care to the emergency room. There is one cardiologist for every 32,000 people in the world. If the answer is already in the ECG, the number of cardiologists shouldn't decide who gets diagnosed in time.

If the answer is already in the ECG, the number of cardiologists shouldn’t decide who gets diagnosed in time.

The years since have been less tidy than that sentence. Willem got its first CE mark in 2024, for 22 cardiac patterns, and clinicians across Europe started using it in their daily practice. We kept researching with more than 150 hospitals and research centres in Europe and the United States. The patients behind more than 730,000 ECGs, from over 34 countries, let their data help someone else. We owe them more than a footnote.

This week we launched Willem 2.0. It is the first and only CE-marked AI-ECG in Europe to help detect both heart failure and ATTR cardiac amyloidosis from a routine 12-lead ECG, and it reads 29 arrhythmias on (almost) any ECG device. Put simply: for the first time, Willem doesn't only describe the rhythm. It helps point to the disease.

We started with these two for a reason. Heart failure affects more than 64 million people¹, and more than half of cases may go undetected². ATTR cardiac amyloidosis is often the patient from the first paragraph: symptoms that look like something else, a first misdiagnosis for 34 to 57% of patients³, and often more than five years from the first symptoms to the right answer⁴. In both, time is the whole story.

What changes is not dramatic on the day. A doctor reads an ECG they would have read anyway. Willem identifies a patient who should see a specialist. That patient gets the right tests sooner than they otherwise would. Fewer visits, fewer wrong turns, and treatment while it can still do the most.

We call it 2.0 because Willem keeps evolving, like the AI models we all use. But the version number isn't the point. The point is that patient, and the next one.

None of this is ours alone. Our team, who have put years of talent and care into Willem. The clinicians and hospitals who trusted us before there was much to trust. The patients whose ECGs make the research possible. And the partners who share the vision.

Hearts beat the same everywhere. For years, the ECG we already had was telling us more than we could hear. Now more doctors can hear it in time.

Manu and Chema, co-founders of Idoven

References

1. Savarese G, et al. Cardiovasc Res. 2022;118:3272-87. 2. Shahim B, et al. Card Fail Rev. 2023;9:e11. 3. Rozenbaum MH, et al. Cardiol Ther. 2021;10:141-59. 4. Mitchell JD, et al. Delays From Clinical Manifestations to Diagnosis of Transthyretin Amyloid Cardiomyopathy: A National Retrospective Cohort Study. J Am Heart Assoc. 2026;e048942.

‍

Authors

Recent articles

November 19, 2026

The ECG we already had

November 17, 2026

Introducing Willem 2.0

September 29, 2025

Donate Your Heartbeats App: turning everyday signals into life-saving knowledge

Contact

Revolutionize cardiovascular care with Idoven. Discuss the possibilities with us.
Thank you!
We will get back to you within 5 days, please check your spam folder
Back to Idoven
Oops! Something went wrong while submitting the form.
Thank you!
We will get back to you within 5 days, please check your spam folder
Back to Idoven
Oops! Something went wrong while submitting the form.
.